SureNano Science’s GEP-44 Triple Agonist Peptide Targets Next-Generation GLP-1 Innovation Amid Rapid Market Growth

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) was featured in a BioMedWire editorial examining the rapid expansion of the GLP-1 market, with the company’s subsidiary GlucaPharm Inc. and its development of GEP-44 positioned as a potential next-generation innovation. The editorial notes that GEP-44, a patented triple agonist peptide licensed from Syracuse University, is designed to target GLP-1 and peptide YY receptors Y1 and Y2, an approach that could address efficacy, tolerability, and delivery flexibility limitations associated with first-generation GLP-1 therapies.

BioMedWire’s coverage places SureNano alongside established and emerging metabolic disease companies, including Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX), and Altimmune (NASDAQ: ALT). The editorial underscores accelerating momentum across the obesity, diabetes, and cardiometabolic treatment landscape, with the global GLP-1 market projected to reach $100 billion by 2030. SureNano’s broader platform strategy includes evaluation of oral, sublingual, and intranasal delivery approaches, as well as early-stage formulation and delivery technologies that could expand its long-term therapeutic scope.

SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP-44 for obesity and metabolic disorders. The initial business of SureNano Science Ltd. involved the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound for nanoemulsions, with exclusive distribution licenses in Canada, Oklahoma, and Colorado. The company is now transitioning to a pharmaceutical focus through its patented therapeutic candidate for obesity and metabolic disease.

Investors can find the latest news and updates relating to SURNF at the company’s newsroom at https://ibn.fm/SURNF. The full press release regarding the BioMedWire editorial is available at https://ibn.fm/2NGrw.